One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Differentiated Thyroid Cancer Therapeutics Market

[ 英語タイトル ] Differentiated Thyroid Cancer Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

Product Code : MDHC0089246
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 121
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Jubilant Life Sciences (Jubilant DraxImage)
- Rosatom State Corporation (JSC Isotope)
- Curium SAS
- Pfizer Inc.
- IBSA Group (IBSA Pharma Inc.)
- Mylan NV
- Sanofi (Genzyme Corporation)
- Exelixis Inc.
- Bayer AG

[Report Description]

The differentiated thyroid cancer (DTC) therapeutics market is expected to register a CAGR of 21.5% during the forecast period. The major factors attributing to the growth of the market are a rise in the incidence of papillary thyroid cancer, which is the most common type of thyroid cancer, accounting for about 80% of all cases. DTC typically doesn't cause any signs or symptoms early in the disease, which results in the development of lumps (nodule) on the neck area, causing difficulties in swallowing, and throat pain, and swollen lymph nodes in the neck.

According to the American Society of Clinical Oncology (ASCO), in 2019, approximately 14,260 men and 37,810 women in the United States were diagnosed with thyroid cancer. It is the most common cancer in women between 20 to 34 years of age, and women are more likely to develop thyroid cancer than men. Furthermore, a rise in government initiatives to control the healthcare burden and growing awareness regarding thyroid cancer treatment options are driving the DTC therapeutics market.

Key Market Trends

The Chemotherapy Segment is Expected to Hold a Major Market Share in the Differentiated Thyroid Cancer Therapeutics Market

- The chemotherapy segment holds a significant market share in the DTC therapeutics market over the forecast period. The dominance is owing to increased use of drugs like doxorubicin, cisplatin, and others as standard treatment. Huge demand can be attributed to the use of combinational drugs and their proven efficiency in preventing cancer progression. These combination drugs reduce the development of drug resistance, which is expected to fuel the market.
- On the other hand, targeted therapy is anticipated to grow at the highest CAGR. The lucrative growth is due to their usage when cancer is progressing. Also, these targeted drugs act differently on thyroid cancer than standard chemotherapy drugs. These agents block tumors from forming new blood vessels and target some of the proteins which increase the growth of cancer cells. The lesser side effects compared to chemotherapy is expected to boost the growth of the segment.

North America is Expected to Hold a Significant Share in the Market and it is Expected to do the Same in the Forecast Period

North America is expected to hold a major market share in the global differentiated thyroid cancer therapeutics market due to rising incidences of PTC, increased mortality rate in this region. For instance, the American Society of Clinical Oncology (ASCO), PTC covers more than 85% of overall thyroid cancers in the United States. Also, according to estimates published by the Thyroid Cancer Survivors' Association, thyroid cancer affects nearly 52,890 new cases in the United States in 2020, which increased from 52,070 cases in the year 2019. Furthermore, the presence of top pharma and biotech companies that are involved in the development of new therapies and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The differentiated thyroid cancer therapeutics market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Bayer AG, Merck Co Inc., Jerome Stevens Pharmaceuticals Inc., Pfizer Inc., Curium SAS.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Assumptions
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Thyroid Cancer
4.2.2 Rising Government Funds and Reimbursement Policies
4.3 Market Restraints
4.3.1 Introduction of Generic Products Due to Patent Expiry of the Branded Drugs
4.3.2 Lack of Awareness about Treatment Options for Thyroid Cancer
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Therapy
5.1.1 Chemotherapy
5.1.2 Targeted Therapy
5.1.3 Thyroid Stimulating Hormone Suppression (THS)
5.1.4 Other Therapies
5.2 Geography
5.2.1 North America United States Canada Mexico
5.2.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.2.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.2.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Jubilant Life Sciences (Jubilant DraxImage)
6.1.2 Rosatom State Corporation (JSC Isotope)
6.1.3 Curium SAS
6.1.5 Pfizer Inc.
6.1.6 IBSA Group (IBSA Pharma Inc.)
6.1.7 Mylan NV
6.1.8 Sanofi (Genzyme Corporation)
6.1.9 Exelixis Inc.
6.1.10 Bayer AG




Recommended reports